Cybin Inc. announced it has engaged Thermo Fisher Scientific to provide U.S.-based manufacturing for its CYB003 program. Thermo Fisher Scientific will support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, Cybin’s proprietary deuterated psilocin program for Major Depressive Disorder (MDD).
Production of both the drug substance and drug product capsules will be performed at Thermo Fisher’s U.S. pharma services manufacturing sites in Florence, South Carolina, and Cincinnati, Ohio. This partnership broadens Cybin's existing relationship with Thermo Fisher, a world leader in serving science.
This affiliation with a world-class manufacturing partner is critical as Cybin advances its Phase 3 CYB003 pivotal program. Securing a robust and reliable supply chain is a key step towards potential regulatory approval and commercialization, especially given CYB003's FDA Breakthrough Therapy Designation received in March 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.